

ADVANCING THERAPEUTIC PARADIGMS FOR OVARIAN CANCER IN THE ERA OF PARP INHIBITORS

A GUIDE FOR THE
ONCOLOGY NURSE



Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from GlaxoSmithKline.




Learning Objectives

- Explore the latest guideline recommendations on ovarian cancer treatment and discuss patient disparities and barriers to receiving guideline recommended care.
- Appraise emerging efficacy trial data with PARP inhibitors in the frontline and recurrent maintenance treatment settings for ovarian cancer.
- Evaluate unique toxicities associated with PARP inhibitor therapy and analyze optimal strategies for the prevention, recognition, and treatment of adverse events.
- Using an interactive, case-based approach, discuss challenging cases regarding the use of PARP inhibitors and examine best practices for oncology nurses to optimize therapy, anticipate and manage adverse events, improve oral adherence and bridge the gap in care for those with socioeconomic and racial disparities.



Accreditation Information

- To receive up to *1.5 ANCC Contact Hours*, scan the QR code located below and in your handout.




E-Syllabus

An electronic version of the handout and program resources are available for download at:

<https://www.ceconcepts.com/content/ons-annual-22>

Or by scanning the QR code below and in your handout.



Meet the Faculty



Paula Anastasia, MN, RN, AOCN

Activity Chair

GYN Oncology

Advanced Practice Nurse

UCLA Health

Los Angeles, California

Meet the Faculty



Jennifer Filipi, MSN, NP

Center for Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

Meet the Faculty



Shannon N. Westin, MD, MPH

Associate Professor

Department of Gynecologic Oncology and Reproductive
Medicine, Division of Surgery

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty Disclosures

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers' bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:

Paula Anastasia, MN, RN, AOCN—has disclosed that she is on the speakers bureau for Genentech and Seagen. She is also on the Merck Advisory Board.

Faculty:

Jennifer Filipi, MSN, NP—has no relevant financial relationships to disclose in relation to the content of this activity.

Shannon N. Westin, MD, MPH—has disclosed that she receives a salary/employment from AstraZeneca, OncXerna Therapeutics Inc, and Roche/Genentech. She has ownership interest/stock or stock options in Bayer, Eisai, and Zentalis. She receives grants from Agenus, EQRx, ImmunoGen, and Merck. She receives research support from Clovis Oncology, Lilly, and Pfizer. She is on the speakers bureau for Cotinga Pharmaceuticals. She is an advisor or consultant for GlaxoSmithKline. She owns stock/shareholder (self managed) in Mereo and receives other financial or material support from Novartis.

Peer Reviewer:

Kristi Acker DNP, PhD, CRNP, FAANP—has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:

Susan H. Gitzinger, PharmD, MPA—has no relevant financial relationships to disclose in relation to the content of this activity.

Tina L. Trieu, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Jessica Hall—has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Special Thanks!



Supported by an independent
educational grant from GlaxoSmithKline
Presented by Creative Educational Concepts, LLC

Meeting space has been assigned to provide a Symposia supported by Creative Educational Concepts and GlaxoSmithKline during the Oncology Nursing Society's (ONS) 47th Annual Congress, April 28 – May 1, 2022 in Anaheim, CA. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.



Poll Everywhere


You may respond via browser or text message
Open your browser and navigate to:

pollev.com/cec182

OR

Text **cec182** to **22333** to connect to our session
and enter your responses (A, B, C, D, etc...)

**You can also use this feature to send questions
to the faculty!**



Web voting



Text voting




Have a Question for the Faculty




Option 1
Poll Everywhere

Option 2
Question Cards located in your Handout Folder



Option 3
Zoom Chat Box



Web voting



Text voting